Tmem185a, a gene of currently not well-defined primary function, may be involved in multiple biological processes related to cancer. It is potentially associated with pathways relevant to tumor metastasis and prognosis determination [1,2,3]. Its study in genetic models could offer insights into its functional mechanisms.

In breast cancer, Tmem185a is among the neoantigens specifically present in lymph node-positive samples, suggesting it could be a potential target for vaccine design to address lymph node metastasis [1].

In urinary bladder cancer, along with TMPRSS11E, SCEL, and KRT78, Tmem185a was identified as part of a four-gene signature. This signature can be used to group patients into high-risk and low-risk groups based on overall survival, and may serve as potential therapeutic targets and diagnostic markers [2].

In stage III serous ovarian carcinoma, TMEM185A was among the down-regulated genes, potentially related to the prognosis of patients [3].

In a case of severe hemophilia A, the rearrangement affected the copy number of TMEM185A along with other genes, though its dosage-dependent biological effects were not clinically detectable other than hemophilia A [4].

In conclusion, Tmem185a appears to be associated with cancer-related processes such as metastasis and prognosis in breast, urinary bladder, and ovarian cancers. Its role in these diseases indicates the potential importance of studying Tmem185a in relevant genetic models, which could provide a better understanding of cancer mechanisms and potentially lead to new treatment strategies.